Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Jianpi Yifei III is a Traditional Chinese Medicine (TCM) formulation developed by the Guangdong Provincial Hospital of Chinese Medicine for the treatment of stable chronic obstructive pulmonary disease (COPD). Administered as oral granules, the drug is designed to address the TCM syndrome of lung-spleen qi deficiency. It is part of a series of 'Jianpi Yifei' formulations (including Jianpi Yifei II) used to manage respiratory and neuromuscular conditions. Clinical evaluation of Jianpi Yifei III focuses on its ability to reduce the frequency of acute exacerbations and improve the quality of life in COPD patients.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Jianpi Yifei III.